Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 5/20 | 0.62 |
| ▸ | ALB | P02768 | 3/20 | 0.60 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | GNPAT | O15228 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18461328 | 0.87 | ALB (0.65) | SIRT5ALBFOLH1SIRT6SIRT1 | |
| SCHEMBL22607329 | 0.86 | SIRT5 (0.54) | SIRT5ALBFOLH1ADRA1AGNPAT | |
| SCHEMBL18800097 | 0.84 | SIRT5 (0.52) | SIRT5ALBFOLH1SIRT6SIRT1 | |
| SCHEMBL20471131 | 0.83 | ALB (0.61) | SIRT5ALBSIRT6SIRT1SIRT2 | |
| SCHEMBL19139063 | 0.83 | SIRT5 (0.54) | SIRT5ALBFOLH1SIRT6SIRT1 | |
| SCHEMBL13635157 | 0.83 | SIRT5 (0.65) | SIRT5ALBFOLH1SIRT6SIRT1 | |
| SCHEMBL12311708 | 0.83 | SIRT5 (0.65) | SIRT5ALBFOLH1SIRT6SIRT1 | |
| SCHEMBL24709112 | 0.81 | FOLH1 (0.48) | SIRT5ALBFOLH1ADRA1AGNPAT | |
| SCHEMBL8280997 | 0.81 | FOLH1 (0.48) | SIRT5ALBFOLH1ADRA1AGNPAT | |
| SCHEMBL20341058 | 0.81 | SIRT5 (0.63) | SIRT5ALBFOLH1ADRA1ANOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308974-B2 | Compounds and methods for detection of enzymes that remove formyl, succinyl, methyl succinyl or myristoyl groups from epsilon-amino lysine moieties | ENZO LIFE SCIENCES, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180223328-A1 | COMPOUNDS AND METHODS FOR DETECTION OF ENZYMES THAT REMOVE FORMYL, SUCCINYL, METHYL SUCCINYL OR MYRISTOYL GROUPS FROM EPSILON-AMINO LYSINE MOIETIES | ENZO LIFE SCIENCES, INC. (US) | 2018-08-09 | — | — | US | disclosed |
| US-9637773-B2 | Compounds and methods for detection of enzymes that remove formyl, succinyl, methyl succinyl or myristoyl groups from ε-amino lysine moieties | ENZO LIFE SCIENCES, INC. (US) | 2017-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180223328-A1 | COMPOUNDS AND METHODS FOR DETECTION OF ENZYMES THAT REMOVE FORMYL, SUCCINYL, METHYL SUCCINYL OR MYRISTOYL GROUPS FROM EPSILON-AMINO LYSINE MOIETIES | EMG1, SPR, SHMT1 | SIRT5 888/4885ALB 3673/4885FOLH1 215/4885 |
| US-10308974-B2 | Compounds and methods for detection of enzymes that remove formyl, succinyl, methyl succinyl or myristoyl groups from epsilon-amino lysine moieties | EMG1, SPR, SHMT1 | SIRT5 888/4885ALB 3673/4885FOLH1 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.